Nigeria has taken another step toward strengthening its public-health preparedness following expanded collaboration between the Nigeria Centre for Disease Control and Prevention (NCDC) and the U.S. Centers for Disease Control and Prevention (CDC).
The partnership, supported by the CDC Foundation, Gates Foundation and other partners, is focused on improving Nigeria’s laboratory-based integrated disease surveillance capacity.
A major component of the initiative is the establishment of a Multiplex Bead Assay (MBA) Laboratory at Nigeria’s National Reference Laboratory in Abuja.
The technology is designed to allow laboratories to examine multiple disease-related markers in a single testing process, strengthening the country’s ability to monitor infectious diseases and generate information needed for public-health decisions.
US Experts Support Capacity Building
As part of the collaboration, a team of U.S. CDC experts spent two weeks at the MBA Laboratory at the Central Public Health Laboratory in Lagos.
The specialists conducted training focused on MBA techniques and the transfer of technical skills, including bead-coupling technology. The programme is intended to build sustainable expertise among Nigerian laboratory professionals rather than relying solely on external technical support.
The initiative is also expected to position Nigeria as a leading MBA laboratory hub in West Africa.
That development could have implications beyond Nigeria because stronger laboratory capacity can support regional disease surveillance and help neighbouring countries respond more effectively to infectious disease threats.
Strengthening Early Detection
Disease surveillance is critical because early detection allows health authorities to investigate unusual disease patterns, identify outbreaks and initiate appropriate interventions before infections spread further.
The U.S. CDC says its work with Nigeria has included strengthening surveillance systems, laboratories and emergency-response capabilities for diseases including monkeypox, yellow fever, measles, Lassa fever, cholera and meningitis.
Nigeria’s experience with the MBA platform also demonstrates the potential value of the technology. Previous work using MBA technology supported large-scale serological studies and generated information used in public-health programmes.
For Nigeria, strengthening laboratory surveillance is particularly important as the country continues to face recurrent outbreaks of infectious diseases.
The latest collaboration therefore represents more than the acquisition of laboratory technology. It is an investment in technical expertise, early warning systems and national health security.
If sustained, the programme could help Nigeria respond faster to emerging threats while strengthening the country’s contribution to disease surveillance across West Africa.
